Nu-Med Plus, Inc. (NUMD) Form 10-Q — Aug 14, 2026
Nu-Med Plus's 10-Q confirms a transformational quarter: on July 8, 2026 the company closed a Share Exchange issuing 4,500,000 Series A Preferred shares to acquire 100% of Avid Gold Ltd in a deal valued at $82,800, pivoting the former nitric oxide medical device maker into Canadian gold exploration. A Mineral Property Purchase Agreement for six gold properties in Nova Scotia, New Brunswick, and Newfoundland and Labrador received 84.5% vendor shareholder approval on August 10, 2026 and is expected to close shortly after this filing.
Key figures
- Revenue
- 0
- Guidance
- Company anticipates no revenue for the year ending December 31, 2026.
- Net Income
- 3792
- Total Assets
- 12909
- Cash Position
- 5409
- Shares Outstanding
- 83548469
- True up cap
- 10% of outstanding common stock
- Q2 net income
- 19670
- Consulting fee
- $5,000 per month per consultant, accrued until $1,000,000 raised
- Yourspace note
- $100,000 at 5% per annum, repayable on or before October 8, 2026
- Total liabilities
- 280395
- True up threshold
- USD $3.0 million vendor proceeds shortfall mechanism
- Accumulated deficit
- 9945722
- Related party notes
- 122500
- Reverse split ratio
- 1-for-27 (proposed, subject to shareholder vote)
- Avid gold deal value
- 82800
- Q2 operating expenses
- 22556
- Tejada voting control
- approximately 48% of outstanding voting shares
- Other income no shop fee
- 45000
- Series a exchange shares
- 4500000
- Series a property shares
- 500000
- Working capital deficiency
- 267486
- Interest expense six months
- 5500
- Potential conversion shares
- up to 110,000,000 common shares if Series A fully converted
- Vendor shareholder approval
- 84.5% of Vendor voting shares (August 10, 2026)
- Series a compensation shares
- 500000
- Six month operating expenses
- 35708
- Avid gold liabilities assumed
- 57137
- Series x shares issued to tejada
- 1000000
- Authorized share increase proposed
- 90,000,000 to 500,000,000
- Net cash used in operations six months
- 5252
AI analysis
Red flags10 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.